Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas (Q33815063)

29 July 2017

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas (English)

1 reference

29 July 2017

Audrey Laroche-Clary

1

1 reference

29 July 2017

Vanessa Chaire

2

1 reference

29 July 2017

Marie-Paule Algeo

3

1 reference

29 July 2017

Marie-Alix Derieppe

4

1 reference

29 July 2017

François L Loarer

5

1 reference

29 July 2017

Antoine Italiano

6

1 reference

29 July 2017

19 June 2017

1 reference

Journal of Hematology & Oncology

29 July 2017

1 reference

29 July 2017

10

1 reference

29 July 2017

1

1 reference

29 July 2017

123

1 reference

describes a project that uses

29 July 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5477309/fullTextXML

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1186/s13045-017-0482-3

0 references

cites work

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Nutlin-3a is a potential therapeutic for ewing sarcoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Well-differentiated and dedifferentiated liposarcomas

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

4 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13045-017-0482-3

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13045-017-0482-3

The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13045-017-0482-3

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13045-017-0482-3

Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477309

Lysing tissue-culture cells for immunoprecipitation

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28629371

12 December 2020

inferred from PubMed ID database lookup

Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28629371

12 December 2020

inferred from PubMed ID database lookup

Freeze-thaw lysis for extraction of proteins from Mammalian cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28629371

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/S13045-017-0482-3

1 reference

Dimensions Publication ID

29 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/s13045-017-0482-3

9 September 2019

1 reference

29 July 2017

1 reference